New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
15:26 EDTSRPTSarepta CEO role in talks with FDA on eteplirsen to be limited, WSJ says
After some of Sarepta Therapeutics' executives worried that CEO Chris Garabedian's involvement in talks with the FDA about its review of the company's DMD drug eteplirsen was counterproductive, the company recently moved to place new limits on his responsibilities to bring them more in-line with other biotech companies of Sarepta's size and maturity, according to The Wall Street Journal, citing people familiar with the matter. Reference Link
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SRPT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use